(a) whether the Government has received any complaints about manufacturing of sub-standard
medicines in excise free States, in pharma companies set up after 2005 under Schedule M;
(b) if so, the details thereof including the number of deaths reported as a result
sub-standard medicines;
(c) whether the introduction of Schedule M drugs have any adverse impact on the competitiveness
of generic medicines manufactured by small scale units; and
(d) if so, the details thereof?